July 14, 2008 07:00 ET

CDEX Inc. and EURAF Announce Business Partnership Relationship

CDEX Inc. and EURAF Enter Into Distribution Agreement for the ValiMed™ Medication Validation System in France

TUCSON, AZ and PARIS--(Marketwire - July 14, 2008) - CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding continued international expansion by announcing today a business partnership agreement with EURAF to distribute ValiMed™ in France. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety and a reduction in medication errors. ValiMed compares a medication's spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

"At EURAF our focus is to provide hospital pharmacies with state-of-the-art technologies to improve workflow and enhance patient medication safety," said Laurent Skvortzoff and Jean-Baptiste Guillot, business associates and managers at EURAF. "ValiMed provides valuable synergies with our pharmacy automation solutions and addresses the critical issue of reliable and safe compounding of IV medication. We are very excited about this new relationship with CDEX."

"France is continuously ranked as one of the leading countries in the world for its healthcare services and the standards and quality of care," said Malcolm Philips, CDEX President and CEO. "We are very pleased that EURAF is joining the CDEX family. We look forward to developing a long and lasting relationship and working together to become a major player in the patient medication safety arena in France."

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. For more information, visit and or contact Steve Schmidt ( or Pascal Pouligny ( at 520.745.5172.


EURAF is a distribution company dedicated to the marketing and servicing of foreign industrial products on the French territory, on an exclusive basis. With a long experience in pharmaceutical processing, packaging and control equipment, EURAF is focusing on two markets with large potential: (a) on line quality control equipment for packaging machinery and (b) equipment for the improvement of the quality of medication delivery in hospital and clinic pharmacies, a market driven by the French government's plan for improvement of security and traceability in the healthcare system. EURAF is one of the leading suppliers in France, with a significant portfolio of complementary products. More information about EURAF can be found at

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the ability to protect proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact Information